Modifi Biosciences announced that it has been acquired by global pharmaceutical giant Merck, with a $30 million down payment.

(Reuters) -Advisers to the Centers for Disease Control and Prevention on Wednesday recommended expanding the use of vaccines ...

With an expanded recommendation from the Center for Disease Control and Prevention (CDC)’s Advisory Committee on Immunization ...

A key panel of US health advisers voted in favor of lowering the age recommendation for vaccines made by Pfizer Inc. and ...

The Global Liver Fibrosis Treatment Industry, valued at USD 16.43 Billion in 2022, is on the brink of an extraordinary surge, ...

Genentech, the biotech unit of Swiss major Roche, has been marketing lung cancer drugs for nearly two decades, starting with ...

Modifi Biosciences, a New Haven startup biotech that focuses on developing cancer therapies, has been acquired by ...

Merck (NYSE:MRK) has acquired Modifi Biosciences, a developer of DNA modification-enabled cancer drugs, for $30M upfront and ...

Yale spinout Modifi agreed to sell to Merck for $30 million upfront. Elsewhere, Sangamo plotted a much faster path to market ...

In a report released today, Akash Tewari from Jefferies maintained a Buy rating on Merck & Company (MRK – Research Report), with a ...

Merck has acquired Modifi Biosciences for as much as $1.3 billion, gaining access to its experimental cancer therapies, the ...

We recently compiled a list of the 8 Most Undervalued Value Stocks To Buy According To Analysts. In this article, we are ...